Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,512.38 -3.89 -0.03%
TOPIX 1,171.40 -1.97 -0.17%
HANG SENG 22,760.24 64.23 0.28%

Galectin Therapeutics: Turning Atlanta into America's Next Silicon Valley



  Galectin Therapeutics: Turning Atlanta into America's Next Silicon Valley

Former Silicon Valley Leaders Say Atlanta Emerging as "Silicon Valley for
Biotech" and Curing Big Diseases

PR Newswire

NORCROSS, Ga., April 4, 2013

NORCROSS, Ga., April 4, 2013 /PRNewswire/ -- Gilbert Amelio, former CEO of
Apple, and Rod Martin, former counsel to PayPal, both on the Board of
Directors of Galectin Therapeutics (NASDAQ: GALT) authored an opinion piece in
today's Atlanta Journal Constitution discussing the future of Atlanta as the
emerging Silicon Valley for changing the world by curing the big diseases, and
why they moved Galectin Therapeutics to Atlanta.

"The world needs a biotech Silicon Valley. We believe that Atlanta is
perfectly poised to become just that," wrote Amelio and Martin.

To read the full op-ed from the Atlanta Journal-Constitution, click here. To
schedule interviews with Gil Amelio and Rod Martin, please contact Cheri
Jacobus at cherijacobus@aol.com, or (202) 257-4638.

About Galectin Therapeutics

Galectin Therapeutics (NASDAQ: GALT) is developing promising
carbohydrate-based therapies for the treatment of fibrotic liver disease and
cancer based on the Company's unique understanding of galectin proteins, key
mediators of biologic function.  We are leveraging extensive scientific and
development expertise as well as established relationships with external
sources to achieve cost effective and efficient development.  We are pursuing
a clear development pathway to clinical enhancement and commercialization for
our lead compounds in liver fibrosis and cancer.  Additional information is
available at www.galectintherapeutics.com.

SOURCE Galectin Therapeutics Inc.

Website: http://www.galectintherapeutics.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement